Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Blood (2024) 144 (Supplement 1): 673.

https://doi.org/10.1182/blood-2024-209653

Published: 2024

Journal Articles

Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial

Blood (2024) 144 (Supplement 1): 385.

https://doi.org/10.1182/blood-2024-209720

Published: 2024

Journal Articles

The Impact of Continuous Lenalidomide Maintenance Treatment on People Living with Multiple Myeloma - a Single-Centre Qualitative Service Evaluation

Caroline Buck, Francisco Castillo, Elena Bettio, Kwee Yong, Annabel Mcmillan, Lydia Sarah Hui Lee, Xenofon Papanikolaou, Ke Xu, Charalampia Kyriakou, Neil Rabin, Ashutosh D. Wechalekar, Rakesh Popat, Joanne Land, Orla McCourt, Helen Poole, Rachel Tarling, Abigail Fisher, Jonathan Sive

Blood (2023) 142 (Supplement 1): 6640.

https://doi.org/10.1182/blood-2023-184914

Published: 2023

Journal Articles

Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study

Blood (2023) 142 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2023-188672

Published: 2023

Journal Articles

Infection Risk and Use of Prophylaxis with Anti-BCMA Bispecific T Cell Engagers and Belantamab Mafodotin for Patients with Relapsed and Refractory Multiple Myeloma

Rakesh Popat, Kathleen Cheok, Amrutha Sridhar, Conor Feely, Catriona Mactier, Annabel Mcmillan, Ashutosh D. Wechalekar, Neil Rabin, Jonathan Sive, Charalampia Kyriakou, Ke Xu, Xenofon Papanikolaou, Shameem Mahmood, Kwee Yong, Lydia Sarah Hui Lee

Blood (2023) 142 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2023-182725

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

Blood (2023) 142 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2023-187202

Published: 2023

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD

Blood (2017) 130 (Supplement 1): 835.

https://doi.org/10.1182/blood.V130.Suppl_1.835.835

Published: 2017

Journal Articles

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Blood (2017) 130 (Supplement 1): 1864.

https://doi.org/10.1182/blood.V130.Suppl_1.1864.1864

Published: 2017

Journal Articles

Clinical Benefit of Depth of Response for Relapsed/Refractory Multiple Myeloma Patients Treated on Clinical Trials: Retrospective Analysis from Two Tertiary Centres

Hian Li Esther Chan, Dunnya De-Silva, Rakesh Popat, MD PhD, Neil Rabin, Ashu Wechalekar, Sufyan Achhala, Adeline Lin, Wee Joo Chng, MB ChB, MRCP, PhD, Kwee Yong, PhD

Blood (2017) 130 (Supplement 1): 1825.

https://doi.org/10.1182/blood.V130.Suppl_1.1825.1825

Published: 2017

Journal Articles

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Blood (2017) 130 (Supplement 1): 1815.

https://doi.org/10.1182/blood.V130.Suppl_1.1815.1815

Published: 2017

Journal Articles

Long Term Outcomes in Monoclonal Gammopathy of Renal Significance (MGRS)

Akhil Khera, Katja Kimberger, Fotios Panitsas, Chris Winearls, John Quinn, Simon Stern, Neil Rabin, Bassam Alchi, Ian Roberts, Richard Haynes, Karthik Ramasamy

Blood (2016) 128 (22): 5948.

https://doi.org/10.1182/blood.V128.22.5948.5948

Published: 2016

Journal Articles

Vial Sharing of Bortezomib Is Logistically Feasible and Significantly Reduces Drug Wastage and the Cost of Myeloma Treatment

Simon Cheesman, Aoife Shields, Raakhee Shah, Nisha Thakrar, Jeff Bradley, Tom Marler-Hausen, Shirley D'Sa, Charalampia Kyriakou, Atul Mehta, MD, Rakesh Popat, Neil Rabin, Ali Rismani, MBBS, Kwee L Yong, Ashu Wechalakar

Blood (2016) 128 (22): 5956.

https://doi.org/10.1182/blood.V128.22.5956.5956

Published: 2016

Journal Articles

Duration of Therapy Is Independently Associated with Improved Progression Free and Overall Survival Following First Line Therapy for Non-Transplant Eligible Patients with Multiple Myeloma: Retrospective Analysis from a Single Centre

Dunnya De-Silva, MBBS, Adam Bloomfield, Nicholas Counsell, Simon Cheesman, BPharm, Ali Rismani, MBBS, Neil Rabin, Shirley D'Sa, Charalampia Kyriakou, Jayne Galinsky, Sarah Richard, Rakesh Popat, Atul Mehta, MD, Kwee L Yong

Blood (2016) 128 (22): 5684.

https://doi.org/10.1182/blood.V128.22.5684.5684

Published: 2016

Journal Articles

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

Nicola Maciocia, MBChB, BSc, MRCP, Andrew Melville, MBBS, MA (Cantab), MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Simon Cheesman, BPharm, Faye Sharpley, MBBChir, MA, MRCP, MSc, Karthik Ramasamy, MD PhD, Matthew Streetly, BMBS, MRCP, MRCPath, Matthew W Jenner, MD, Reuben Benjamin, MB, BS, FRCPath, Stephen A Schey, MD, Rakesh Popat, Shirley D'Sa, Ali Rismani, MBBS, Kwee L Yong, Neil Rabin

Blood (2016) 128 (22): 3312.

https://doi.org/10.1182/blood.V128.22.3312.3312

Published: 2016

Journal Articles

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

Selina J Chavda, MBBS BSc MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Pavlina Mesiri, MSc, Nicholas Counsell, Jaimal Kothari, FRCPath, Antonia Bird, Ciaran Mariner, Anastasia Chew, MBBS, MRCP, FRCPATH, Katherine Clesham, MBBS, Sally Moore, BSc, FRPATH, FRCP, MBBS, Laura Percy, MBBS, MRCP, FRCPATH, Ali Rismani, MBBS, Shirley D'Sa, Rakesh Popat, Neil Rabin, Kwee L Yong

Blood (2016) 128 (22): 3465.

https://doi.org/10.1182/blood.V128.22.3465.3465

Published: 2016

Journal Articles

Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival

Melody Chin, BSc, MSc, Jonathan Sive, MBBS, Christopher Allen, BSc, Claire Roddie, MD PhD, Selina J Chavda, MBBS BSc MRCP, Dean Smith, MBBS, Rakesh Popat, Ali Rismani, MBBS, Shirley D'Sa, Neil Rabin, Rosemary E. Gale, PhD BSc, Kwee L Yong

Blood (2016) 128 (22): 4455.

https://doi.org/10.1182/blood.V128.22.4455.4455

Published: 2016

Journal Articles

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Oliver C Cohen, MBBS MRCP, Neil Rabin, Nicholas Counsell, Roger G Owen, MD PhD, Bilyana Popova, Oliver Schofield, Janet Lyons-Lewis, Andy Rawstron, Christopher Spence, Ruth Mary de Tute, PhD FRCPath, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Sally Moore, BSc, FRPATH, FRCP, MBBS, Paul Smith, PhD, Kwee L Yong

Blood (2016) 128 (22): 4508.

https://doi.org/10.1182/blood.V128.22.4508.4508

Published: 2016

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Kwee L Yong, MBChB, PhD, Sarah Brown, Samantha Hinsley, Louise Flanagan, Neil Rabin, MB,BS, PhD, Karthik Ramasamy, Jamie Cavenagh, Roger G Owen, Martin F Kaiser, MD, Eric Low, Catherine Williams

Blood (2015) 126 (23): 1840.

https://doi.org/10.1182/blood.V126.23.1840.1840

Published: 2015

Journal Articles

Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Arash Latifoltojar, MB BS, MSc, MPhil, Kwee L Yong, MBChB, PhD, Margaret Hall-Craggs, BA, MB BS, MD, Neil Rabin, MB,BS, PhD, Rakesh Popat, MBBS, PhD, Alan Bainbridge, Magdalena Sokolska, Nikolaos Dikaios, Shirley D'Sa, MD FRCP, FRCPath, Ali Rismani, MBBS, Shonit Punwani, Mb BS, BSc, PhD

Blood (2015) 126 (23): 1850.

https://doi.org/10.1182/blood.V126.23.1850.1850

Published: 2015

Journal Articles

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Blood (2014) 124 (21): 4745.

https://doi.org/10.1182/blood.V124.21.4745.4745

Published: 2014

NARROW

IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial

The Impact of Continuous Lenalidomide Maintenance Treatment on People Living with Multiple Myeloma - a Single-Centre Qualitative Service Evaluation

Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study

Infection Risk and Use of Prophylaxis with Anti-BCMA Bispecific T Cell Engagers and Belantamab Mafodotin for Patients with Relapsed and Refractory Multiple Myeloma

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Clinical Benefit of Depth of Response for Relapsed/Refractory Multiple Myeloma Patients Treated on Clinical Trials: Retrospective Analysis from Two Tertiary Centres

Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation

Long Term Outcomes in Monoclonal Gammopathy of Renal Significance (MGRS)

Vial Sharing of Bortezomib Is Logistically Feasible and Significantly Reduces Drug Wastage and the Cost of Myeloma Treatment

Duration of Therapy Is Independently Associated with Improved Progression Free and Overall Survival Following First Line Therapy for Non-Transplant Eligible Patients with Multiple Myeloma: Retrospective Analysis from a Single Centre

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only